Introduction {#Sec1}
============

Iron deficiency is the most common and widespread nutritional disorder in the world.\[[@CR1]--[@CR4]\] It is estimated to account for 50% of anemia cases and is considered one of the most important factors contributing to the burden of disease worldwide.\[[@CR5]\] The latest WHO survey, based on data gathered between 1993 and 2005, estimated the worldwide prevalence of anemia in pregnant women to be 41.8%.\[[@CR5]\]

Recent evidence suggests that all grades of anemia increase the risk of death.\[[@CR6]\] Severe anemia is associated with an increased risk of maternal and child mortality.\[[@CR5]\] Severe anemia may directly cause maternal death from heart failure, but moderate anemia is also a factor that can influence a woman's ability to prevent and/or recover from complications in pregnancy or post-partum, such as hemorrhage and infection.\[[@CR6]\]

The risk of folate deficiency is also increased during pregnancy (mainly during periods of rapid fetal growth) and lactation (when folate is lost in breast milk).\[[@CR7]\] In pregnancy, among other complications, the risk of neural tube defects\[[@CR8]\] may be increased up to 10-fold, depending on folate status.\[[@CR7]\]

Furthermore, deficiencies of folate and iron usually occur together, are particularly common during pregnancy, lactation, and the post-partum period, and are the two leading causes of nutritional deficiency anemia.\[[@CR9]\] However, it has been reported that concomitant administration of iron and folic acid facilitates a better physiological response to the treatment of iron deficiency in pregnancy than iron alone.\[[@CR10]\]

Neither iron nor folic acid has been shown to be pharmacologically active, but both play complex roles in the normal metabolism of the body. Both iron and folate are necessary for the normal functioning of the hematopoietic system, as well as many other essential metabolic processes.\[[@CR7]\]

The WHO recommends universal supplementation for all pregnant women with iron 60 mg/day and folic acid 400 μg/day, from as early as possible in pregnancy.\[[@CR11]\] However, despite this, anemia continues to be one of the most common causes of disease in pregnancy.\[[@CR6],[@CR11]\]

Different combinations of iron- and folic acid-containing supplements are commercially available, some of which contain similar amounts of elemental iron. However, there are no published studies comparing the bioavailability and bioequivalence of these combinations containing both iron and folic acid. Indeed, evaluating the *in vivo* bioequivalence of such supplements can be difficult to manage, because iron is both a physiological constituent of the body and is present in variable quantities in food. Similarly, the formulation (e.g. a slow-release formulation) and solubility of the particular iron salt can also influence the bioavailability.\[[@CR12]--[@CR14]\] In these cases, *in vitro* dissolution may be a more appropriate assessment method.

Furthermore, iron-containing drugs have undesirable side effects on the gastric mucosa; therefore, it is common to design oral slow-release formulations in order to improve tolerability and adherence to treatment.\[[@CR15]\] Under these conditions, it might be appropriate to evaluate the release rate of iron over time by performing a dissolution test.\[[@CR16]\] These tests evaluate the *in vitro* dissolution rate (giving important information on the probable bioavailability of the products) and allow assessment of the degree of similarity between products to indicate their *in vitro* bioequivalence.\[[@CR17]\]

The aim of this study was to compare the *in vitro* dissolution of six tablets of two iron- and folic acid-containing supplements, Folifer® and Ferroliver®.

MaterialsAndMethods {#Sec2}
===================

Of the supplements commercially available for iron-deficiency anemia prevention, two iron- and folic acid-containing combinations were selected, which contained different iron salts but similar amounts of elemental iron. Folifer® (Bialport --- Produtos Farmacêuticos, S.A., Portugal) is available in film-coated tablet form, each tablet consisting of a central core, containing approximately 90 mg of iron (as ferrous sulfate granules), and 1 mg of folic acid. For comparison purposes, Ferroliver® (SM Pharma c.a., Venezuela) was used, another iron-containing supplement in tablet form. Ferroliver® contains slightly more iron (99 mg, as ferrous fumarate) compared with Folifer® and a different amount of folic acid (400 μg), as well as containing other compounds, including 0.0005 mg of vitamin B~12~ and 1 mg of copper sulfate.

Reagents and Solutions {#Sec3}
----------------------

The following reagents and solutions were used: concentrated hydrochloric acid 35--37% (Sigma), iron sulfate (II) \[Merck\], concentrated sulfuric acid 95--97% (Merck), sodium hydroxide (Sigma), monopotassium phosphate (Merck), ammonium sulfate (Merck), cerium (Merck), potassium iodide (Sigma), sodium thiosulfate (Merck), soluble starch (Sigma), and mercuric iodide (Sigma).

The reagents and solutions were prepared as follows:

*Solution of ammonium sulfate and 0.1 M cerium:* 65 g of ammonium sulfate and cerium was dissolved and mixed with 30 mL of concentrated sulfuric acid and 500 mL of water. The mixture was cooled and a further 1000 mL of water was added. Then, 25 mL of ammonium sulfate and cerium was added to 2 g of potassium iodide and 150 mL of water. This was titrated immediately with 0.1 M sodium thiosulfate, using 1 mL of starch solution as an indicator.

*Solution of ammonium sulfate and 0.01 M cerium:* 50 mL of ammonium sulfate and 0.1 M cerium was diluted with 500 mL water.

*Starch solution:* 1.0 g of soluble starch was ground with 5 mL of water and poured, stirring constantly, into 100 mL of boiling water, to which 10 mg of mercuric iodide was added.

*Gastric juice (pH 1.5):* 90 mL of concentrated hydrochloric acid and 84 mL of 10 M sodium hydroxide were transferred to a 10 L container. This mixture was stirred, and approximately 9 L of water was added until the pH reached 1.50 ± 0.05. The solution was then made up to 10 L with water.

*Intestinal juice (pH 4.5):* 8.7 g of monopotassium phosphate was added to a 10 L container. Water was added to the mixture, which was stirred and diluted to 1 L. 38 mL of 10 M sodium hydroxide and 30 mL of concentrated hydrochloric acid were then added. The solution was stirred and adjusted until the pH was 4.50 ± 0.05. The solution was then made up to 10 L with water.

*Intestinal juice (pH 6.9):* The same procedure was used as described in preparation of the intestinal juice pH 4.5, except the pH was adjusted to 6.90 ± 0.05.

Equipment {#Sec4}
---------

Weighing was carried out using a Mettler Toledo XS205 balance. The dissolution tests were carried out using the Vankel VK700 dissolution testing station, while the titrimetric determination of iron was evaluated using a Radiometer TIM800 automatic titrator.

*In Vitro* Dissolution Test {#Sec5}
---------------------------

The amount of iron released from each tablet was evaluated over a 4-hour period, using the Vankel VK700 dissolution testing station and one of three dissolution media replicating gastric or intestinal juices with pH values ranging from 1.5 to 6.9. The test was performed by transferring 750 mL of gastric juice (pH 1.5) to six dissolution vessels and allowing the temperature to stabilize at 37.0 ± 0.5°C. One tablet was placed in each rotating basket within each vessel to begin the dissolution test at 50 rpm. After 1 hour, a 200 mL sample was removed from each of the six dissolution vessels and accurately measured, and 20 mL of sulfuric acid 1 M was added. To quantify the amount of iron released, this sample was then titrated with a solution of cerium ammonium sulfate 0.01 M, using a platinum electrode as the indicator electrode and mercury as a reference electrode.\[[@CR18]\]

The remainder of the medium in the dissolution vessel was then discarded and replaced with intestinal juice pH 4.5, which was allowed to stabilize to 37.0 ± 0.5°C for 5 minutes, and the test proceeded for a further 1-hour rotation period to allow further dissolution of the tablet. After 1 hour, another 200 mL sample was then taken from each vessel and measured precisely, and 20 mL of sulfuric acid 1 M was added. This was then titrated with a solution of cerium ammonium sulfate 0.01 M, using a platinum electrode as the indicator electrode and mercury as a reference electrode. The procedure was then repeated using intestinal juice with a pH of 6.9 and a rotation period of 2 hours.

These conditions were established in order to have a minimum of three timepoints, covering the early, middle and late stages of the dissolution profile, with the last timepoint corresponding to the plateau of the dissolution profile.\[[@CR19]\] Moreover, these three timepoints are sufficient to draw a dissolution profile that can be used to compare the different formulas.

The experimental method was validated as per the International Conference on Harmonisation (ICH) guideline Q2\[[@CR20]\] and the United States Pharmacopeia.\[[@CR16]\] Linearity was assessed for the three pHs by plotting three calibration plots, with a correlation coefficient of 1.0000. Repeatability and intermediate precision were assessed by analyzing two sets of six tablets on different days, with different analysts. The overall relative standard deviation was less than 10% as per the validation protocol for the three dissolution media, while the absolute difference between mean dissolution values for each pH was less than 10%. Accuracy was evaluated for each pH by spiking placebo with known amounts of iron (II). A mean recovery index within 100 ± 2% was obtained for the three dissolution media. Robustness was evaluated by changing the critical parameters of the method. The results obtained were within 100 ± 5% of the results obtained under standard conditions.

Statistical Methods {#Sec6}
-------------------

The percentage of dissolved iron for each tablet at each timepoint was calculated as a cumulative frequency, using the percentage of dissolved iron at all timepoints that had been analyzed up to that point. For each timepoint, the mean percentage of dissolved iron was calculated from the six tablets, together with the relative standard deviation. The mean values were plotted in dissolution curves for the two products under evaluation and allowed comparison by means of the similarity factor, *f*~2~ ([equation 1](#Equ1){ref-type=""}). $$\documentclass[12pt]{minimal}
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The similarity factor is a logarithmic reciprocal square root transformation of the sum of squared errors and is a measurement of the similarity in the percentage of dissolution between the two curves. At least three mean dissolution results from both curves obtained at the same timepoints were used for the calculations. An *f*~2~ value of between 50 and 100 suggests that the two dissolution profiles are similar.

Results {#Sec7}
=======

The results of the dissolution profiles and degree of similarity for the two products are shown in [table I](#Tab1){ref-type="fig"} and [figures 1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}.

![Mean amount of iron released from two iron- and folic acid-containing supplements, Folifer® and Ferroliver®: results from an in vitro dissolution study](40268_2012_12010035_Tab1){#Tab1}

![Dissolution profiles showing the mean percentage of iron released over a 4-hour time period for Folifer® and Ferroliver®.](40268_2012_12010035_Fig1){#Fig1}

![Dissolution profiles showing the mean absolute amount of iron released over a 4-hour time period for Folifer® and Ferroliver®.](40268_2012_12010035_Fig2){#Fig2}

During the first hour, 29.7 mg and 32.7 mg of iron was released from Folifer® and Ferroliver®, respectively. In percentage terms, the release rate was similar, as the iron content of the two supplements was similar. During the second hour, Folifer® showed a higher capacity for releasing iron than Ferroliver®, both in absolute terms and in relative terms. After 4 hours, the amounts of iron released by Folifer® and Ferroliver® were 59.4 mg and 48.5 mg, respectively.

The mean comparative dissolution profiles of Folifer® and Ferroliver® were also assessed by determining the similarity factor, *f*~2~, according to the formula shown in equation 1. The *f*~2~ value between the two formulations was 41, showing a lack of similarity and *in vitro* bioequivalence.

Discussion {#Sec8}
==========

*In vitro* dissolution studies can provide important information on bioavailability and bioequivalence of various formulations. A dissolution test can be used as a tool to identify formulation factors that influence, and may have a crucial effect on, the bioavailability of a drug. Appropriate *in vitro* dissolution testing may be used in place of *in vivo* bioequivalence testing. Accordingly, dissolution testing should be investigated at different pH values (normally pH 1.2, 4.5, and 6.8).

Results from our *in vitro* dissolution study showed Folifer® was superior to Ferroliver®, releasing 59.4 mg versus 48.5 mg of iron over a 4-hour period, respectively, indicating that Folifer® is likely to have increased bioavailability compared with Ferroliver®. This result is even more surprising considering that Ferroliver® has a slightly higher elemental iron content.

In this respect, the role of the different iron salts in each drug --- ferrous sulfate (in Folifer®) and ferrous fumarate (in Ferroliver®) --- should be noted. Ferrous sulfate has an improved dissolution profile compared with ferrous fumarate because of its superior degree of solubility in acid.\[[@CR21]\] This difference is likely to be the main reason for the observed results and the lack of equivalence between the two products.

However, since the two products differ slightly in their chemical composition, we cannot exclude the possibility of bias in the study. While we recognize that this is a potential limitation of this study, there is no known scientific rationale for folic acid, vitamin B~12~, or copper sulfate significantly influencing the *in vitro* dissolution of iron. The selectivity of cerimetric titration for the quantitation of iron (II) in the presence of inert excipients was demonstrated in the validation results. Excipients and other active ingredients found in the formulas were not expected to have any relevant influence on the assay, as they either did not have any relevant oxidation-reduction behavior, or they were present at very low levels relative to the amount of iron.

Finally, the information that arises from application of the formula for calculating the similarity factor (equation 1) shows both drugs have different *in vitro* dissolution profiles and so are unlikely to be bioequivalent.

This study reinforces the importance and differentiation of ferrous sulfate and ferrous fumarate as iron salts. Previous evidence suggests that different iron salts show similar tolerability in clinical use.\[[@CR22]\] In two studies comparing the absorption of ferrous sulfate and ferrous fumarate from fortified milk-based drinks, one study found that ferrous sulfate was better absorbed than ferrous fumarate,\[[@CR23]\] while absorption of ferrous sulfate and ferrous fumarate did not differ significantly in the second study.\[[@CR24]\] Given the significant effects that the type of salt may have on *in vitro* dissolution, ferrous sulfate-containing supplements such as Folifer® may therefore be a better choice for iron/folic acid supplementation in individuals at risk of iron/folate deficiencies, such as pregnant and lactating women.

Conclusion {#Sec9}
==========

Despite containing similar amounts of elemental iron, Folifer® showed greater dissolution of iron compared with Ferroliver®. This study highlights the importance of some iron salts (such as ferrous sulfate) on the bioavailability of iron supplements. Folifer® and Ferroliver® had dissimilar dissolution profiles *in vitro*; differences in the solubility of ferrous sulfate and ferrous fumarate may explain the lack of equivalence, and this should be considered in clinical practice.
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